论文部分内容阅读
目的:采用Meta分析评估miR-17-92簇高表达在肿瘤患者预后中的价值。方法:检索Web of Science、Pub Med、EMBASE数据库从建库至2015年10月1日关于miR-17-92簇成员高表达与恶性肿瘤患者预后关系的英文文献,提取关键数据,计算合并风险比(hazard ratio,HR)及其95%置信区间(confidence interval,CI)。结果:共纳入39篇文献,包含4 908例患者。miR-17-92簇的高表达与恶性肿瘤患者总生存率(HR=1.83,95%CI:1.58~2.12,P=0.000)低有关,并且miR-17-92簇高表达的肿瘤患者的无病生存率(HR=1.80,95%CI:1.43~2.26,P=0.000)、无进展生存率(HR=1.83,95%CI:1.11~3.02,P=0.018)及肿瘤特异性生存率(HR=1.59,95%CI:1.04~2.42,P=0.032)均降低;然而无复发生存率的合并风险比无统计学意义(P=0.539)。结论:miR-17-92簇高表达与恶性肿瘤患者的不良预后有关,有望成为新型肿瘤预后标志物。
OBJECTIVE: To evaluate the value of miR-17-92 cluster in the prognosis of cancer patients by Meta-analysis. METHODS: The English literature on the relationship between the high expression of miR-17-92 cluster members and the prognosis of patients with malignant tumors was constructed from the Web of Science, Pub Med and EMBASE databases from construction to October 1, 2015. The key data were extracted and the risk ratio of combined (hazard ratio, HR) and its 95% confidence interval (CI). Results: A total of 39 articles were included, covering 4,908 patients. The high expression of miR-17-92 cluster was associated with a low overall survival (HR = 1.83, 95% CI: 1.58-2.12, P = 0.000) in patients with malignant tumors and no tumor-bearing patients with miR-17-92 cluster (HR = 1.80, 95% CI: 1.43-2.26, P = 0.000), progression-free survival rate (HR = 1.83, 95% CI: 1.11-3.02, P = 0.018) and tumor-specific survival rate = 1.59, 95% CI: 1.04-2.42, P = 0.032). However, there was no statistically significant difference in the risk of recurrence without recurrence (P = 0.539). Conclusion: The high expression of miR-17-92 cluster is associated with poor prognosis in patients with malignant tumors and is expected to become a new tumor prognostic marker.